Literature DB >> 15661995

Medicine. Treating neurodegenerative diseases with antibiotics.

Timothy M Miller1, Don W Cleveland.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661995     DOI: 10.1126/science.1109027

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  10 in total

1.  Long-term exposure of variable dietary protein-to-carbohydrate ratio: effect on brain regional glutamatergic activity with age.

Authors:  Sudipta Pal; Mrinal K Poddar
Journal:  Neurochem Res       Date:  2007-09-01       Impact factor: 3.996

Review 2.  Novel glutamatergic agents for major depressive disorder and bipolar disorder.

Authors:  Rodrigo Machado-Vieira; Lobna Ibrahim; Ioline D Henter; Carlos A Zarate
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

Review 3.  Glutamatergic modulators: the future of treating mood disorders?

Authors:  Carlos Zarate; Rodrigo Machado-Vieira; Ioline Henter; Lobna Ibrahim; Nancy Diazgranados; Giacomo Salvadore
Journal:  Harv Rev Psychiatry       Date:  2010 Sep-Oct       Impact factor: 3.732

4.  Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress.

Authors:  Jian-Xin Chen; Li-Hua Yao; Bi-Bo Xu; Kun Qian; Hui-Ling Wang; Zhong-Chun Liu; Xiao-Ping Wang; Gao-Hua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 5.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

6.  The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.

Authors:  S M Rawls; R Tallarida; W Robinson; M Amin
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 7.  The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Neuroscientist       Date:  2009-05-26       Impact factor: 7.519

8.  Fluoxetine treatment induces EAAT2 expression in rat brain.

Authors:  M Zink; S Rapp; R Donev; P J Gebicke-Haerter; J Thome
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

9.  Reduction of EEG theta power and changes in motor activity in rats treated with ceftriaxone.

Authors:  Michele Bellesi; Vladyslav V Vyazovskiy; Giulio Tononi; Chiara Cirelli; Fiorenzo Conti
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

10.  PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene.

Authors:  Anna-Liisa Brownell; Darshini Kuruppu; Kun-Eek Kil; Kimmo Jokivarsi; Pekka Poutiainen; Aijun Zhu; Michelle Maxwell
Journal:  J Neuroinflammation       Date:  2015-11-24       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.